Switch theme
Sign up to access all valuation multiples
Guard Therapeutics International AB is engaged in developing and commercializing the lead drug candidate ROSgard, and thereby contribute to the better and less harmful treatment of acute kidney injuries.
1974
14
Last FY Revenue n/a
LTM EBITDA -$11.6M
$32.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Guard Therapeutics Intl has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$11.6M.
In the most recent fiscal year, Guard Therapeutics Intl achieved revenue of n/a and an EBITDA of -$9.9M.
Guard Therapeutics Intl expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Guard Therapeutics Intl valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$11.6M | XXX | -$9.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$11.6M | XXX | -$10.3M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$11.4M | XXX | -$9.9M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Guard Therapeutics Intl's stock price is SEK 18 (or $2).
Guard Therapeutics Intl has current market cap of SEK 367M (or $37.9M), and EV of SEK 313M (or $32.3M).
See Guard Therapeutics Intl trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $32.3M | $37.9M | XXX | XXX | XXX | XXX | $-0.86 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Guard Therapeutics Intl has market cap of $37.9M and EV of $32.3M.
Guard Therapeutics Intl's trades at n/a EV/Revenue multiple, and -3.3x EV/EBITDA.
Equity research analysts estimate Guard Therapeutics Intl's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Guard Therapeutics Intl has a P/E ratio of -3.3x.
See valuation multiples for Guard Therapeutics Intl and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $37.9M | XXX | $37.9M | XXX | XXX | XXX |
| EV (current) | $32.3M | XXX | $32.3M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -2.8x | XXX | -3.3x | XXX | XXX | XXX |
| EV/EBIT | -2.8x | XXX | -3.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.3x | XXX | -3.8x | XXX | XXX | XXX |
| EV/FCF | -2.7x | XXX | -3.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGuard Therapeutics Intl's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.7M for the same period.
Guard Therapeutics Intl's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Guard Therapeutics Intl's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Guard Therapeutics Intl and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -105% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Guard Therapeutics Intl acquired XXX companies to date.
Last acquisition by Guard Therapeutics Intl was XXXXXXXX, XXXXX XXXXX XXXXXX . Guard Therapeutics Intl acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Guard Therapeutics Intl founded? | Guard Therapeutics Intl was founded in 1974. |
| Where is Guard Therapeutics Intl headquartered? | Guard Therapeutics Intl is headquartered in Sweden. |
| How many employees does Guard Therapeutics Intl have? | As of today, Guard Therapeutics Intl has 14 employees. |
| Is Guard Therapeutics Intl publicy listed? | Yes, Guard Therapeutics Intl is a public company listed on STO. |
| What is the stock symbol of Guard Therapeutics Intl? | Guard Therapeutics Intl trades under GUARD ticker. |
| When did Guard Therapeutics Intl go public? | Guard Therapeutics Intl went public in 2013. |
| Who are competitors of Guard Therapeutics Intl? | Similar companies to Guard Therapeutics Intl include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Guard Therapeutics Intl? | Guard Therapeutics Intl's current market cap is $37.9M |
| Is Guard Therapeutics Intl profitable? | Yes, Guard Therapeutics Intl is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Guard Therapeutics Intl? | Guard Therapeutics Intl's last 12 months EBITDA is -$11.6M. |
| What is the current EV/EBITDA multiple of Guard Therapeutics Intl? | Current EBITDA multiple of Guard Therapeutics Intl is -2.8x. |
| What is the current FCF of Guard Therapeutics Intl? | Guard Therapeutics Intl's last 12 months FCF is -$12.0M. |
| What is the current EV/FCF multiple of Guard Therapeutics Intl? | Current FCF multiple of Guard Therapeutics Intl is -2.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
